Skip to main content
. 2020 Jun 24;11:3196. doi: 10.1038/s41467-020-16838-w

Fig. 7. Prot-FOLR1-TCB can be activated by patient-derived ovary cancer explants.

Fig. 7

Jurkat NFAT reporter assay was used to analyze activation of Prot-FOLR1-TCB (matA or MMP-matA linker) ex vivo by undigested human tumor explants. a Benign tumor of the ovary. b Cancer of the ovary. c Cancer of the ovary. Explants were mechanically cut and then incubated with TCBs and analyzed for CD3 activation using Jurkat NFAT cells. Jurkat NFAT activation is measured in relative luminescence units (RLU). Each symbol indicates the value measured for one biological sample incubated with Jurkat NFAT cells and Prot-FOLR1-TCB MMP-matA site (gray bar), matA site (purple bar), noncleavable site (blue bar) or FOLR1-TCB (red bar). a Each data point shows the mean of technical duplicates measured for one well (n = 2 biological replicates). b Each data point shows the value measured for one well (n = 3 biological replicates). Standard deviation is indicated by error bars. c Each data point shows the mean of technical duplicates measured for one well (n = 2 biological replicates). The dotted lines indicate luminescence for Jurkat NFAT-cells incubated with tumor samples but without any TCB.